Shin is the Chief Scientific Officer and Head of Research at HCRx. He leads HCRx’s research efforts as well as sourcing related to universities, research institutions and inventors. Since he joined HGRx in 2015, Shin has successfully integrated HCRx’s research efforts into both the investment and business development processes. Prior to joining HCRx, he served as a vice president of equity research at Wells Fargo Securities covering the biotechnology sector.
Previously, Shin managed technology, intellectual property and business development at the Mount Sinai School of Medicine. He holds a Ph.D. in Biological Chemistry/Immunology from the University of California, Los Angeles, an M.B.A. from Columbia Business School and a B.S. from the University of California, Davis. Dr. Kang also conducted research at Genentech as a postdoctoral fellow.